Payment overview · 2025
General Payments
$216.85
8 reported records · 6 companies
Healthcare provider profile · identity verified
Francelot Moise, MD
Allopathic & Osteopathic Physicians|Family Medicine · MIRAMAR, FL · NPI 1528007721
Verified facts
What the public records show
CMS Open Payments records show Francelot Moise, MD received $216.85 in general payments during 2025 across 8 reported records.
Boston Scientific Corporation accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $46.25 | 21.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.67 | 21.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.96 | 19.4% | 2 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $39.60 | 18.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.37 | 10.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.00 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $216.85 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $46.25 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $45.67 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.96 | 2 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $39.60 | 1 | 2025 |
Source payment records
|
|||||
| NUVISION ICE CATHETER Normalized: nuvision ice catheter |
Device | Biosense Webster, Inc. | $39.60 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 222 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
222 | 50 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Nifedipine Er | Nifedipine | 650 | 172 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 561 | 149 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 348 | 97 |
| Famotidine | Famotidine | 311 | 122 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 281 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 276 | 71 |
| Metformin Hcl | Metformin Hcl | 264 | 69 |
| Gabapentin | Gabapentin | 252 | 71 |
| Celecoxib | Celecoxib | 229 | 128 |
| Farxiga | Dapagliflozin Propanediol | 222 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 60 |
| Allopurinol | Allopurinol | 202 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 168 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 135 | 36 |
| Meloxicam | Meloxicam | 128 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 123 | 38 |
| Mirtazapine | Mirtazapine | 122 | 38 |
| Jardiance | Empagliflozin | 120 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 27 |
| Carvedilol | Carvedilol | 116 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 33 |
| Omeprazole | Omeprazole | 113 | 36 |
| Latanoprost | Latanoprost | 108 | 23 |
| Glimepiride | Glimepiride | 104 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 33 |
| Furosemide | Furosemide | 95 | 29 |
| Clonidine | Clonidine | 94 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 90 | 22 |
| Alendronate Sodium | Alendronate Sodium | 84 | 22 |
| Tadalafil | Tadalafil | 79 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 67 |
| Eliquis | Apixaban | 76 | 14 |
| Irbesartan | Irbesartan | 74 | 17 |
| Januvia | Sitagliptin Phosphate | 74 | 15 |
| Trulicity | Dulaglutide | 70 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 15 |
| Meclizine Hcl | Meclizine Hcl | 60 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 11 |
| Tradjenta | Linagliptin | 59 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 53 | suppressed |
| Ezetimibe | Ezetimibe | 53 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 31 |
| Glipizide Er | Glipizide | 48 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 35 |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | suppressed |
| Novolog Flexpen | Insulin Aspart | 41 | 17 |
| Lumigan | Bimatoprost | 40 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 39 | 13 |
| Losartan Potassium | Losartan Potassium | 36 | 11 |
| Megestrol Acetate | Megestrol Acetate | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 24 |
| Glipizide | Glipizide | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 12 |
| Dorzolamide Hcl | Dorzolamide Hcl | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Advocate Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 26 | 14 |
| Mupirocin | Mupirocin | 25 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 17 |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | 11 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | 14 |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | 12 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Mesalamine Er | Mesalamine | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lisinopril | Lisinopril | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $216.85 · 8 records | Boston Scientific Corporation | CARTO 3, Dexcom G6 Transmitter, FARXIGA, MOUNJARO, NUVISION ICE CATHETER, The Cologuard Plus Collection Kit, WATCHMAN FLX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error